ESMO2023

Home Tag

Banner web VHIO (1300 × 600 px) (28)

Multiparametric magnetic resonance imaging as a non-invasive predictor of response to immune checkpoint inhibitors

Reported today at the ESMO Congress 2023 in Madrid, results of a VHIO prospective study point to the promise of…

564x380 web VHIO (5)

Results of LIBRETTO-531 support selpercatinib as first-line treatment in patients with RET-mutant metastatic medullary thyroid cancer

Presented during Presidential session I (1) at the 2023 Congress of the European Society for Medical Oncology (ESMO), 20-24 October…

Banner web VHIO (1300 × 600 px) (27)

First-in-class HIF-2α inhibitor improves outcomes in patients with previously treated advanced clear cell renal cell carcinoma

Presented today at the ESMO Congress 2023, results of the phase III LITESPARK-005 study show that treatment with belzutifan versus…